# Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

> **NCT05583357** · EARLY_PHASE1 · UNKNOWN · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 40 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** V-01D-351
- **BIOLOGICAL:** V-01D-351
- **BIOLOGICAL:** CoronaVac
- **BIOLOGICAL:** CoronaVac

## Key facts

- **NCT ID:** NCT05583357
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-15
- **Primary completion:** 2022-09-13
- **Final completion:** 2023-08-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583357, "Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05583357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*